DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant's election with traverse the species of “immunoassay”, biopsy sample, sotigalimab, and PD-1 inhibitor/pembrolizumab in the reply filed on 7 August 2026 is acknowledged. The traversal is on the ground(s) that there is no lack of unity finding only that the Markush groupings do not share both structural similarity and function (pg. 2, paragraphs 1-2). This is not found persuasive because as disclosed in MPEP chapter 1800, The Unity Standard applies to Markush groupings of chemical compounds or alternatives (PCT Rule 13.2). The Markush grouping complies with PCT unity requirements if all alternatives meet the following criteria:
All alternatives must have a common property or activity, and
A significant structural element must be shared by all of the alternatives, OR all alternatives must belong to a recognized class of chemical compounds in the art to which the invention pertains. Recognized chemical class means that the alternatives are substitutable for each other and produce the same physiological effect.
The Requirement for Restriction/Election adequately explains how the alternatives of Groups A, B, C and D do not ALL share both a common structure and a common property/activity that flows from that common structure. Nor do the alternatives constitute obvious variants such that they can be substituted for each other such that the methods produce identical results. Therefore, the requirement is still deemed proper and is therefore made FINAL.
Claim 41-60 will be examined upon their merits.
Priority
Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. This application is a national stage entry of PCT/US22/74696 which claims the benefits of US Provisional Application No. 63/231,428 filed on 10 August 2021. Claims 41-60 have an effective US filing date of 10 August 2021.
Information Disclosure Statement
The information disclosure statements (IDSs) submitted on 2 July 2024 and 11 June 2025 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.
Improper Markush Grouping Rejection
Claims 45, 51 and 57-58 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117.
The Markush grouping of Claims 45, 51 and 57-58 are improper because the alternatives defined by the Markush grouping do not share both a single structural similarity and a common use that flows from said shared structural similarity.
To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within an improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 41-60 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for administering the CD40 agonist sotigalimab in melanoma patients who have increased sCD8A and decreased CCL17, or administering the CD40 agonist sotigalimab in melanoma patients who have increased expression of CD4, CD40, and CCL14 and decreased expression of ABCF1, TP53, TCF3, and HDAC11, or administering sotigalimab to patients with PD-L1 negative tumors, or patients previously having undergone prior nivolumab or pembrolizumab or prior anti-CTLA5 therapy; the specification does not reasonably provide enablement for the method comprising any other CD40 agonist. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
The factors to be considered in determining whether a disclosure would require undue experimentation include:
A) The breadth of the claims;
(B) The nature of the invention;
(C) The state of the prior art;
(D) The level of one of ordinary skill;
(E) The level of predictability in the art;
(F) The amount of direction provided by the inventor;
(G) The existence of working examples; and
(H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.
In re Wands, 8 USPQ2d, 1400 (CAFC 1988) and MPEP 2164.01.
Breadth of the claims: With respect to claim breadth, the standard under 35 U.S.C. §112, first paragraph, entails the determination of what the claims recite and what the claims mean as a whole. In addition, when analyzing the scope of enablement, the claims are analyzed with respect to the teachings of the specification and are to be “given their broadest reasonable interpretation consistent with the specification.” See MPEP 2111 [R-5]; Phillips v. AWH Corp., 415 F.3d 1303, 75 USPQ2d 1321 (Fed. Cir. 2005); and In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). Applicant always has the opportunity to amend the claims during prosecution, and broad interpretation by the examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than is justified. In re Prater, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550- 51 (CCPA 1969).
As such, the broadest reasonable interpretation of the claimed method is that it provides treatment for melanoma comprising administering any CD40 agonist to a subject with increased sCD8 levels and decreased CCL17. A skilled artisan would not know how to use the method with a reasonable expectation of success based solely on what is disclosed in the specification.
Existence of working examples: The working example are all directed to methods comprising administering the CD40 agonist sotigalimab in melanoma patients who have increased sCD8A and decreased CCL17, in melanoma patients who have increased expression of CD4, CD40, and CCL14 and decreased expression of ABCF1, TP53, TCF3, and HDAC11, or to patients with PD-L1 negative tumors, or patients previously having undergone prior nivolumab or pembrolizumab or prior anti-CTLA5 therapy. However, the breadth of the claims encompass the administration of any CD40 agonist despite the fact that the working examples establish responsiveness specific to sotigalimab alone. Thus, what is enabled by the working examples is narrow in comparison to the breadth of the claim.
The level of predictability in the art: the current state of the art teaches CD40 agonists are not necessarily interchangeable, for example, SEA-CD40 and sotigalimab differ significantly in their antibody backbone engineering, Fc receptor engagement, and mechanisms of action (Coveler et al., Journal for ImmunoTherapy of Cancer; 11:e005584, 2023).
The standard of an enabling disclosure is not the ability to make and test if the invention works but one of the ability to make and use with a reasonable expectation of success. A patent is granted for a completed invention, not the general suggestion of an idea and how that idea might be developed into the claimed invention. In the decision of Genentech, Inc, v. Novo Nordisk, 42 USPQ 2d 1001, (CAFC 1997), the court held that:
"[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable" and that "[t]ossing out the mere germ of an idea does not constitute enabling disclosure". The court further stated that "when there is no disclosure of any specific starting material or of any of the conditions under which a process is to be carried out, undue experimentation is required; there is a failure to meet the enablement requirements that cannot be rectified by asserting that all the disclosure related to the process is within the skill of the art", "[i]t is the specification, not the knowledge of one skilled in the art, that must supply the novel aspects of an invention in order to constitute adequate enablement".
The quantity of experimentation needed to make or use the invention based on the content of the disclosure: The instant specification is not enabling because one cannot follow the guidance presented therein, or within the art at the time of filing, and practice the claimed method without first making a substantial inventive contribution. Given that the nature of the invention, a person having ordinary skill in the art would have to perform further experimentation in order to demonstrate that the expression levels associated with responsiveness to sotigalimab, are also indicative of the efficacy of other CD40 agonists. The amount of experimentation required for enabling guidance, goes beyond what is considered ‘routine’ within the art, and constitutes undue further experimentation in order to use the method, as claimed, with a reasonable expectation of success. Therefore, Claims 41-60 are rejected under 35 U.S.C. 112, first paragraph, for failing to meet the enablement requirement.
Conclusion
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to STACEY NEE MACFARLANE whose telephone number is (571)270-3057. The examiner can normally be reached M-F 7:30-5 (EST) & Sat. A.M..
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/STACEY N MACFARLANE/Examiner, Art Unit 1675